| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $8,785,113 | 42 | 100 |
| LEVIN ARTHUR A | director | 0 | $0 | 1 | $22,264 | $-22,264 |
| Hoitt Jason | Chief Patient Officer | 0 | $0 | 2 | $119,311 | $-119,311 |
| Leggett Thomas | Chief Financial Officer | 0 | $0 | 2 | $147,145 | $-147,145 |
| TZIANABOS ARTHUR | Interim Executive Chair | 0 | $0 | 1 | $174,214 | $-174,214 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC | 0 | $0 | 11 | $1.32M | $-1.32M |
| Kaye Edward M. MD | director | 0 | $0 | 6 | $1.37M | $-1.37M |
| Ticho Barry | CHIEF MEDICAL OFFICER | 0 | $0 | 16 | $1.88M | $-1.88M |
| Krainer Adrian R. | director | 0 | $0 | 4 | $3.9M | $-3.9M |
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet …
Over the last 12 months, insiders at Stoke Therapeutics, Inc. have bought $0 and sold $8.79M worth of Stoke Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Stoke Therapeutics, Inc. have bought $0 and sold $28.55M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 375,000 shares for transaction amount of $14.63M was made by Harrison Seth Loring () on 2020‑11‑24.
| 2026-10-02 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 627 0.001% | $26.33 | $16,509 | -1.72% | |
| 2026-10-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 1,051 0.0016% | $26.16 | $27,494 | -2.65% | |
| 2026-09-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 5,545 0.0085% | $30.67 | $170,061 | -15.64% | |
| 2026-08-18 | Sale | Kaye Edward M. MD | director | 12,567 0.0194% | $32.03 | $402,528 | -17.72% | |
| 2026-08-18 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 4,767 0.0074% | $32.03 | $152,690 | -17.72% | |
| 2026-08-18 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 2,861 0.0044% | $32.03 | $91,639 | -17.72% | |
| 2026-08-03 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 7,176 0.0107% | $29.04 | $208,385 | -4.77% | |
| 2026-07-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 7,228 0.0116% | $32.66 | $236,068 | -10.73% | |
| 2026-06-16 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 1,457 0.0024% | $29.95 | $43,637 | +1.06% | |
| 2026-06-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 1,795 0.0029% | $30.58 | $54,891 | -3.43% | |
| 2026-05-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 2,243 0.0038% | $32.79 | $73,548 | -9.87% | |
| 2026-04-01 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 1,838 0.0032% | $32.66 | $60,029 | -5.85% | |
| 2026-03-20 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 9,293 0.0158% | $33.69 | $313,038 | -9.28% | |
| 2026-03-19 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 1,461 0.0023% | $29.99 | $43,815 | -8.30% | |
| 2026-03-18 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 6,686 0.0118% | $31.34 | $209,569 | -1.77% | |
| 2026-03-18 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 4,628 0.0082% | $31.34 | $145,063 | -1.77% | |
| 2026-03-18 | Sale | Hoitt Jason | Chief Patient Officer | 1,931 0.0034% | $31.34 | $60,526 | -1.77% | |
| 2026-03-18 | Sale | Leggett Thomas | Chief Financial Officer | 2,382 0.0042% | $31.34 | $74,663 | -1.77% | |
| 2026-03-17 | Sale | Ticho Barry | CHIEF MEDICAL OFFICER | 6,164 0.0108% | $33.01 | $203,451 | -7.26% | |
| 2026-03-17 | Sale | Allan Jonathan | GENERAL COUNSEL & CORP SEC | 4,267 0.0075% | $33.01 | $140,838 | -7.26% |
| Harrison Seth Loring | 17161713 26.5965% | $463.19M | 2 | 0 | <0.0001% | |
| Apple Tree Partners IV, L.P. | 10 percent owner | 17161713 26.5965% | $463.19M | 2 | 0 | <0.0001% |
| RTW INVESTMENTS, LP | 10 percent owner | 3544248 5.4927% | $95.66M | 6 | 1 | <0.0001% |
$8,217,280 | 112 | 46.33% | $1.6B | |
$607,395,062 | 99 | 4.23% | $1.88B | |
$54,660,406 | 66 | 22.24% | $1.5B | |
$47,419,530 | 58 | 17.20% | $1.96B | |
$61,893,001 | 38 | 19.63% | $1.89B |
| Increased Positions | 99 | +59.64% | 8M | +12.06% |
| Decreased Positions | 71 | -42.77% | 8M | -11.24% |
| New Positions | 44 | New | 3M | New |
| Sold Out Positions | 12 | Sold Out | 1M | Sold Out |
| Total Postitions | 194 | +16.87% | 69M | +0.82% |
| Fmr Llc | $212,130.00 | 12.04% | 6.87M | -547,925 | -7.39% | 2025-09-30 |
| Blackrock, Inc. | $185,012.00 | 10.5% | 5.99M | +62,874 | +1.06% | 2025-09-30 |
| Lynx1 Capital Management Lp | $167,004.00 | 9.48% | 5.4M | 0 | 0% | 2025-09-30 |
| Rtw Investments, Lp | $158,317.00 | 8.99% | 5.12M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $143,186.00 | 8.13% | 4.63M | 0 | 0% | 2025-09-30 |
| Redmile Group, Llc | $129,024.00 | 7.33% | 4.18M | -200,389 | -4.58% | 2025-09-30 |
| Morgan Stanley | $109,295.00 | 6.21% | 3.54M | -36,926 | -1.03% | 2025-09-30 |
| Toronto Dominion Bank | $98,054.00 | 5.57% | 3.17M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $97,764.00 | 5.55% | 3.16M | +217,616 | +7.39% | 2025-09-30 |
| Skorpios Trust | $69,716.00 | 3.96% | 2.26M | -1M | -30.71% | 2025-09-30 |